Datroway approved in EU for breast cancer treatment
Datroway (datopotamab deruxtecan), developed by Daiichi Sankyo and AstraZeneca (NYSE:AZN), received European Union approval as a monotherapy treatment for adults with unresectable or metastatic triple negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.










